Abstracts tagged "polymorphism and temporal arteritis"

Abstract Number: 776 • 2014 ACR/ARHP Annual Meeting
A Candidate Gene Approach Identifies IL33 as a Novel Genetic Risk Factor for GCA
Ana Márquez¹, Roser Solans², José Hernández-Rodríguez³, Maria C. Cid⁴, Santos Castañeda⁵, Marc Ramentol⁶, Luis Rodriguez-Rodriguez⁷, Javier Narváez⁸, Ricardo Blanco⁹, Norberto Ortego-Centeno¹⁰, Øyvind Palm¹¹, Andreas P. Diamantopoulos¹², Niko Braun¹³, Frank Moosig¹⁴, Torsten Witte¹⁵, Lorenzo Beretta¹⁶, Claudio Lunardi¹⁷, Marco A. Cimmino¹⁸, Augusto Vaglio¹⁹, Carlo Salvarani²⁰, Miguel A. Gonzalez-Gay²¹ and Javier Martin²², ¹Instituto de Parasitologia y Biomedicina López-Neyra (IPBLN-CSIC) and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ²Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036- Barcelona, Spain, ⁵Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain, ⁶Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain, ⁷Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ⁹Hospital Marques de Valdecilla, Santander, Spain, ¹⁰Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹¹Department of Rheumatology, Oslo University Hospital and University of Oslo, Oslo, Norway, ¹²Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ¹³Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany, ¹⁴Department of Clinical Immunology and Rheumatology, University of Luebeck, Bad Bramstedt, Germany, ¹⁵Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ¹⁶Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁷Department of Medicine, Università degli Studi di Verona, Verona, Italy, ¹⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ¹⁹Unit of Nephrology, University Hospital of Parma, Parma, Italy, ²⁰Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ²¹Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, ²²Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: IL-33, through binding to its receptor ST2 (suppression of tumorigenicity 2), encoded by the interleukin 1 receptor-like 1 (IL1RL1) gene, activates mast cells and…
Abstract Number: 777 • 2014 ACR/ARHP Annual Meeting
Influence of the IL17A Locus in Giant Cell Arteritis Susceptibility
Javier Martin¹, Ana Márquez², José Hernández-Rodríguez³, Maria C. Cid⁴, Roser Solans⁵, Santos Castañeda⁶, Inmaculada C. Morado⁷, Javier Narváez⁸, Victor M. Martinez-Taboada⁹, Norberto Ortego-Centeno¹⁰, Bernardo Sopeña¹¹, Jordi Monfort¹², Maria Jesus Garcia-Villanueva¹³, Luis Caminal-Montero¹⁴, Eugenio De Miguel¹⁵, Ricardo Blanco¹⁶, Øyvind Palm¹⁷, Øyvind Molberg¹⁸, Joerg Latus¹⁹, Niko Braun¹⁹, Frank Moosig²⁰, Torsten Witte²¹, Lorenzo Beretta²², Alessandro Santaniello²³, Giulia Pazzola²⁴, Luigi Boiardi²⁵, Carlo Salvarani²⁶ and Miguel A. Gonzalez-Gay⁹, ¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²Instituto de Parasitologia y Biomedicina López-Neyra (IPBLN-CSIC) and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036- Barcelona, Spain, ⁵Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁶Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ⁹Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, ¹⁰Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹¹Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ¹²Department of Rheumatology, Grup de recerca cel•lular en inflamació i cartílag. IMIM (Institut de Recerca Hospital del Mar), Barcelona, Spain, ¹³Department of Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, ¹⁴Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁵Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ¹⁶Hospital Marques de Valdecilla, Santander, Spain, ¹⁷Department of Rheumatology, Oslo University Hospital and University of Oslo, Oslo, Norway, ¹⁸Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ¹⁹Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany, ²⁰Department of Clinical Immunology and Rheumatology, University of Luebeck, Bad Bramstedt, Germany, ²¹Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²²Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²³Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²⁴Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²⁵Unita` Operativa di Reumatologia, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ²⁶Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy
Background/Purpose: A recent study has showed that the number of Th17 lymphocytes is significantly increased in patients with GCA, resulting in an imbalance between Th17…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].